Anika Therapeutics Outlines Strategic Growth for Cingal and Hyalofast Amid $3B Market Opportunity

Anika Therapeutics presented its strategic vision for advancing Cingal and Hyalofast during the Canaccord MSK Conference, underscoring a projected $3 billion total addressable market in the orthopedic biologics segment. The company revealed plans to expand clinical access, enhance manufacturing capacity, and target new geographic markets over the next three years. Cingal, a viscosupplement for osteoarthritis, is being positioned for broader adoption in the U.S. and Europe, supported by ongoing real-world evidence studies. Hyalofast, an injectable hyaluronic acid-based therapy, is expected to expand its indications and distribution channels to capture additional market share in pain management and joint preservation therapies. The company reported that Cingal achieved 18% year-over-year revenue growth in early 2025, while Hyalofast demonstrated a 22% increase, driven by increased physician adoption and expanded reimbursement coverage. These gains are attributed to targeted sales force initiatives and strategic partnerships with specialty distributors. Anika noted that both products are currently available in over 40 countries, with a focus on deepening penetration in high-growth emerging markets such as India, Brazil, and Southeast Asia. Financially, the company projects that Cingal and Hyalofast combined will account for over 60% of total revenue by 2028, up from 47% in 2024. This shift reflects a strategic pivot toward higher-margin, differentiated biologics within the company’s portfolio. The expansion plans are backed by internal R&D investments and a $120 million capital allocation dedicated to product lifecycle management and regulatory submissions in key regions.